Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial Hengwei Wu, MDa,b,c,* ∙ Wenming Shi, PhDd,* ∙ Zhuoyue Shi, MDa,b,c,* ∙ Yi Luo, MDa,b,c ∙ Jian Yu, MDa,b,c ∙ Weijie Cao, MDe ∙ et al.

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial Hengwei Wu, MDa,b,c,* ∙ Wenming Shi, PhDd,* ∙ Zhuoyue Shi, MDa,b,c,* ∙ Yi Luo, MDa,b,c ∙ Jian Yu, MDa,b,c ∙ Weijie Cao, MDe ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00167-5/abstract?dgcid=raven_jbs_etoc_feature_lanhae